Free Trial

TransCode Therapeutics (RNAZ) Earnings Date, Estimates & Call Transcripts

TransCode Therapeutics logo
$7.01 +0.04 (+0.57%)
As of 10:27 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TransCode Therapeutics Earnings Summary

TransCode Therapeutics released Q4 2024 earnings on May 21, 2025, reporting an EPS of -$0.60, which topped analysts' consensus estimates of -$2.00 by $1.40. With a trailing EPS of $0.00, TransCode Therapeutics' earnings are expected to grow next year, from ($4.76) to ($4.37) per share.

Latest Q4
Earnings Date
May. 21Estimated
Consensus EPS
(May. 21)
-$2.00
Actual EPS
(May. 21)
-$0.60 Beat By $1.40
Get TransCode Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TransCode Therapeutics and other key companies, straight to your inbox.

Sign Up
Skip Charts & View Estimated and Actual Earnings Data

RNAZ Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TransCode Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20251-$56.00-$56.00-$56.00
Q2 20251-$8.68-$8.68-$8.68
Q3 20251-$9.24-$9.24-$9.24
Q4 20251-$10.08-$10.08-$10.08

TransCode Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/21/2025Q4 2024-$2.00-$0.60+$1.40-$2.51$0.30M-
8/14/2024Q2 2024-$535.92-$683.76 -$147.84-$0.74--
5/15/2024Q1 2024-$646.80-$600.60+$46.20-$0.65--
11/14/2023Q3 2023-$55,440.00-$62,092.80 -$6,652.80-$1.68--
8/14/2023Q2 2023-$125,294.40-$121,598.40+$3,696.00-$3.29--

TransCode Therapeutics Earnings - Frequently Asked Questions

TransCode Therapeutics (NASDAQ:RNAZ) last announced its quarterly earning data on Wednesday, May 21, 2025. Learn more on RNAZ's earnings history.

In the previous quarter, TransCode Therapeutics (NASDAQ:RNAZ) reported ($0.60) earnings per share (EPS) to beat the analysts' consensus estimate of ($2.00) by $1.40. Learn more on analysts' earnings estimate vs. RNAZ's actual earnings.

TransCode Therapeutics (NASDAQ:RNAZ) has a recorded net income of -$18.55 million. RNAZ has generated $0.00 earnings per share over the last four quarters.

TransCode Therapeutics's earnings are expected to grow from ($4.76) per share to ($4.37) per share in the next year.

More Earnings Resources from MarketBeat



This page (NASDAQ:RNAZ) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners